These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19601849)

  • 1. Therapeutic potential of peptide motifs--part II.
    Hervé JC
    Curr Pharm Des; 2009; 15(21):2375-6. PubMed ID: 19601849
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic potential of peptide motifs against HIV-1 reverse transcriptase and integrase.
    Andréola ML
    Curr Pharm Des; 2009; 15(21):2508-19. PubMed ID: 19601847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.
    Welsh CF
    Breast Cancer Res Treat; 2004 Mar; 84(1):33-42. PubMed ID: 14999152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
    Steffen I; Pöhlmann S
    Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antimicrobial peptides: a potential arsenal against HIV infection].
    Castañeda-Delgado JE; Cervantes-Villagrana AR; Rivas-Santiago B
    Invest Clin; 2012 Mar; 53(1):71-83. PubMed ID: 22524110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immunity. Ancient system gets new respect.
    Gura T
    Science; 2001 Mar; 291(5511):2068-71. PubMed ID: 11256394
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic potential of peptide motifs - part III.
    Hervé JC
    Curr Pharm Des; 2010; 16(9):1021-3. PubMed ID: 20236078
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclin-dependent kinase inhibitors move into Phase III.
    Guha M
    Nat Rev Drug Discov; 2012 Dec; 11(12):892-4. PubMed ID: 23197022
    [No Abstract]   [Full Text] [Related]  

  • 9. The emergence of peptides as therapeutic drugs for the inhibition of HIV-1.
    Huther A; Dietrich U
    AIDS Rev; 2007; 9(4):208-17. PubMed ID: 18219364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
    Pumfery A; de la Fuente C; Berro R; Nekhai S; Kashanchi F; Chao SH
    Curr Pharm Des; 2006; 12(16):1949-61. PubMed ID: 16787240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
    Bruyère C; Meijer L
    Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
    Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
    ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
    Luciani MG; Hutchins JR; Zheleva D; Hupp TR
    J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinases as therapeutic targets in melanoma.
    Miller DM; Flaherty KT
    Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rho/Rho kinase as a potential target for the treatment of renal disease.
    Wakino S; Kanda T; Hayashi K
    Drug News Perspect; 2005 Dec; 18(10):639-43. PubMed ID: 16491166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
    Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
    Cruz M; Reinert T; Cristofanilli M
    Clin Pharmacol Ther; 2018 Jun; 103(6):1009-1019. PubMed ID: 29226311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.